Skip to main content

MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma (2017)
Journal Article
Moody, H. L., Lind, M. J., & Maher, S. G. (2017). MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma. Molecular Therapy - Nucleic Acids, 8(15 September 2017), 317-329. https://doi.org/10.1016/j.omtn.2017.07.001

Malignant pleural mesothelioma (MPM) is associated with an extremely poor prognosis, and most patients initially are or rapidly become unresponsive to platinum-based chemotherapy. MicroRNA-31 (miR-31) is encoded on a genomic fragile site, 9p21.3, whi... Read More about MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma.

MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma (2015)
Journal Article
Bibby, B. A. S., Reynolds, J. V., & Maher, S. G. (2015). MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma. PloS one, 10(7), https://doi.org/10.1371/journal.pone.0134180

Oesophageal adenocarcinoma (OAC) is the sixth most common cause of cancer deaths worldwide, and the 5-year survival rate for patients diagnosed with the disease is approximately 17%. The standard of care for locally advanced disease is neoadjuvant ch... Read More about MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma.

Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma (2014)
Journal Article
Lynam-Lennon, N., Maher, S. G., Maguire, A., Phelan, J., Muldoon, C., Reynolds, J. V., & O'Sullivan, J. (2014). Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma. PloS one, 9(6), e100738. doi:10.1371/journal.pone.0100738

Neoadjuvant chemoradiation therapy (CRT) is increasingly the standard of care for locally advanced oesophageal cancer. A complete pathological response to CRT is associated with a favourable outcome. Radiation therapy is important for local tumour co... Read More about Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma.

Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation (2011)
Journal Article
Maher, S. G., McDowell, D. T., Collins, B. C., Muldoon, C., Gallagher, W. M., & Reynolds, J. V. (2011). Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Annals of Surgery, 254(5), 809-816. https://doi.org/10.1097/SLA.0b013e31823699f2

OBJECTIVE: To identify serum-based biomarkers predicting response to neoadjuvant chemoradiotherapy (neo-CRT) in esophageal cancer. PURPOSE: Increasingly, the standard of care for esophageal cancer involves neo-CRT followed by surgery. The identificat... Read More about Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation.

Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer (2009)
Journal Article
Maher, S. G., Gillham, C. M., Duggan, S. P., Smyth, P. C., Miller, N., Muldoon, C., …Reynolds, J. V. (2009). Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Annals of Surgery, 250(5), 729-737. doi:10.1097/SLA.0b013e3181bce7e1

OBJECTIVE:This study explored gene expression differences in predicting response to chemoradiotherapy in esophageal cancer. PURPOSE:A major pathological response to neoadjuvant chemoradiation is observed in about 40% of esophageal cancer patients and... Read More about Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer.


;